AstraZeneca is one of the COVID-19 vaccines that are being distributed worldwide. While there is positive feedback, there are worrying reports as well, and this is why some countries have suspended the inoculation of the citizens using the AstraZeneca vaccine.
CNN News reported that three countries, including Denmark, Iceland, and Norway, have announced their move to stop the use of the Oxford-AstraZeneca vaccine. The countries stated they would resume the vaccinations once the European Union's medicines regulator clears the vaccine from possible link to the reported formation of blood clots.
Denmark stressed the suspension of AstraZeneca is temporary
Health regulators are investigating the reports of blood clotting, so in the meantime, Denmark announced a 2-week suspension for vaccinations using the AstraZeneca brand. Norway and Iceland also declared the pullout of the said vaccine but did not say when they will bring back AstraZeneca.
Denmark’s minister of health, Magnus Heunicke, reiterated that the move is just a precautionary measure and the vaccine could be used again later. "We act early, it needs to be thoroughly investigated," he tweeted.
"We are in the middle of the largest and most important vaccination rollout in Danish history. And right now we need all the vaccines we can get,” Søren Brostrøm, Danish National Board of Health director, said in a statement. “Therefore, putting one of the vaccines on pause is not an easy decision but we need to clarify this before we can continue to use the vaccine from AstraZeneca."
The cases of blood clotting
The mentioned three countries paused the use of AstraZeneca vaccines that were developed together with the University of Oxford. This action was taken due to the reports of severe blood clots in individuals who have received their shot of the AstraZeneca vaccine.
This is quite fatal, according to the accounts, and it was not just one person, but several of them have reported the same condition of clotting. There was also a report of death, but it is still not certain if the vaccine caused it or contributed to the case. With these incidents, the government immediately halted the inoculations.
“Patient safety is the highest priority for AstraZeneca,” AstraZeneca told CNBC in response to the suspensions. “Regulators have clear and stringent efficacy and safety standards for the approval of any new medicine, and that includes COVID-19 Vaccine AstraZeneca. The safety of the vaccine has been extensively studied in Phase III clinical trials.”
Meanwhile, AstraZeneca stocks went down by 2.5% on Thursday, following the news of the vaccines' possible adverse effects.


Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 



